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Targeting the mouse genome:
a compendium of knockouts (part I)
It has been about six years since publication of the first
papers to demonstrate the feasibility of mutating a specific
mouse gene by homologous recombination in embryonic
stem cells and of then transferring the mutation into a
developing mouse. This ability to engineer specific muta-
tions represented a major breakthrough in mouse genet-
ics, and many excellent reviews discussing its development
and implementation have been published (for example
[1-3]). The most common point of this exercise has been
to inactivate the targeted gene and to observe the pheno-
typic effects of the 'knockout' on the developing mouse.
A number of reviews describing results from knockout
mice relevant to specific areas of mammalian biology have
been published (for example [4-6]). The purpose of this
article is to provide a compendium of the gene-targeted
mutations that have been published, with the hope that
this will become the foundation for an active database that
will keep track of this burgeoning field.
Logistics
In developing two tables of knockouts, we have attemp-
ted to compile all of the published genomic modifica-
tions that have been established in murine embryonic
stem cells by homologous recombination, passed through
the germ line of chimeric mice, and then studied in
resulting heterozygous, hemizygous and/or homozygous
animals. In most cases, the result of targeting has been a
null mutation, but truncations and subtle modifications
of the protein coding sequence, as well as modifications
of non-coding sequences, are also included in our com-
pendium. This is clearly a limited subset of a large group
of interesting mouse mutants, including those that have
occurred spontaneously or have been developed by ran-
dom integration of transgenes or viral sequences. How-
ever, Table 1 does include the majority of mouse mutants
for which the exact gene mutation has been character-
ized. In several cases a targeted mutation has produced a
phenotype similar to a previously studied mouse mutant,
and has thus facilitated the molecular characterization of
the previously established mutant [7-131.
The first column of Table 1 gives the name of the protein
product of the targeted gene (with abbreviated and/or
alternative names in parentheses), or a description of the
targeted genomic locus if it is not a coding sequence. If
the entry is not a null mutant, this is also indicated by, for
example, 'modification' or 'partial' (a 'leaky' mutation). The
table is alphabetized by the first column. In cases where
more than one group has performed essentially the same
mutation, the number of independent groups is indicated
in the second column (e.g. x2, x3). Also in the second
column, we note if the mutant has been crossed with
another mutant derived by gene targeting, and studied as
a double mutant; this is indicated by a 'D', preceded by
the number of different double mutants (e.g. D, 2D). The
double mutants are described in a separate table (Table 2)
which will be published in part III in a subsequent issue.
The third column gives a synopsis of the key aspects of
the phenotype, generally those reported in the primary
reference(s) listed in the fourth column. By necessity, this
description is superficial, and we direct the reader to the
primary sources for more critical and in-depth analyses.
When embryonic lethality is associated with the muta-
tion, this is indicated by an 'e' followed by the day(s) of
gestation when the mutants die. Perinatal lethality is
defined as death within the first 24-48 hours after birth,
and neonatal lethality is death before weaning. In many
cases the perinatal and neonatal lethality is highly variable
and may depend on the genetic background or environ-
ment, and again the reader is referred to the primary
references for the precise details.
In a few instances, when more than one group has
created essentially the same mutant, disparate results have
been reported. Regardless of the reason for the disagree-
ment, these findings are marked with a * in the third col-
umn. The fourth column gives the reference(s) that first
described the mutant, while the fifth column lists sub-
sequent reports describing the mutant, or utilizing the
mutant as a tool for other experiments.
We have attempted to be comprehensive through 1994 in
our compilation, and have also included some reports
published in the first quarter of 1995. It is likely, how-
ever, that our search strategies (scanning major journals
and searching Medline and Reference Update by key
words) have inadvertently missed important references
through 1994. We apologize to any researchers whose
mutants or follow-up studies have escaped our attention
and urge authors to submit this information to Current
Biology for inclusion in updates to the database. A box on
the next page tells you how to do this.
Observations
A total of 327 independently derived mutants are
included in this table. However, essentially only 263 fun-
damentally different protein disruptions (or genetic modi-
fications) have been performed, as 52 null mutations have
been established independently by two different groups,
and six by three groups. This degree of duplication of
knockouts is not particularly surprising given the number
of groups that have focused their research efforts on the
same genes, and merely attests to the allure of the
approach. It seems that certain types of protein have been
preferentially studied so far (for example, those involved
in immune responses or embryonic development). But
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the range is now expanding as the technology becomes
more accessible.
In certain cases, unexpected roles for a protein have been
discovered. In other cases, genetic redundancy or com-
pensation has allowed partial function despite the absence
of a protein thought to be crucial. In fact, out of the 263
knockouts listed in the table, only about 25 % lead to
lethality before or just after birth, with another 10 % re-
sulting in death during the first three to six weeks. Most
null mutants, however, survive into adulthood. A com-
mon early misconception - that null mutants often have
no observable defects - can be dispelled by the compen-
dium. In fact, only a dozen or so of the mutants are appar-
ently normal, and we suspect that, given further study,
defects will be discovered in some of these mutants as well.
Several null mutants have demonstrated a surprisingly
high degree of phenotypic variability between individual
mice. This is probably due to the mixed genetic back-
ground on which the mutants are often initially derived,
a contention supported by the reduction in variability
observed when mutations are placed onto uniform inbred
backgrounds [14-17]. Additionally, environmental factors
(such as the position of the embryo in utero or the ani-
mals' housing conditions) may be at least partially res'
ponsible for phenotypic variations between individuals,
and especially for those found between similar mutants
performed by independent groups.
Future
What can we predict for the future of this technology?
While it certainly appears that many more gene knock-
outs will be reported, extrapolation of the number pub-
lished per year (Fig. 1) suggests that the rate may level off
at a few hundred new reports per year. A number of fac-
tors could serve to limit this rate, including the relatively
large financial cost of both mouse colonies and technical
support. However, the payoff is great: the gene disruptions
already available have facilitated research in virtually all
areas of mammalian physiology and cell biology, and there
will be further benefits from studies using either mutant
mice or cells derived from these animals. This collection
of mutant animals provides a compelling resource for the
future of biomedical research and a vital counterpart to
the human and mouse genome sequencing projects.
Fig. 1. The number of knockouts reported each year.
Knockout mice have not always provided straight-
forward answers to pressing questions, and this has led to
a certain amount of disillusionment with the approach
itself. Indeed, many mutants created by gene targeting
have resulted more in confusion than clarification. But
with the emergence of more questions than answers it
becomes clearer than ever just how complex many
mammalian systems are, and entire new areas of inves-
tigation are sometimes opened up. The future holds the
promise of producing mice carrying specific mutations
in genes rather than complete null mutants. Tissue-
specific or developmentally regulated mutations are now
also feasible, and these techniques should allow a much
more focused analysis of specific gene function. A
largely unexplored area of research involves the develop-
ment of either primary or established cell lines from
null mutant mice; these cells should prove valuable in
studies of the functional roles of gene products without
the complicated context of the whole animal. Thus,
the knockout mice represent not an end point but a
starting point.
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